FINWIRES · TerminalLIVE
FINWIRES

Faeth Therapeutics' Experimental Cancer Drug Piktor Has Upside Potential, Oppenheimer Says

By

Faeth Therapeutics' (FTH) investigational cancer drug Piktor has a differentiated potential and may see 24% upside from trial results in Q4, followed by breast cancer data next year that may unlock additional value, Oppenheimer said in a note emailed Tuesday.

Oppenheimer said it is estimating risk-adjusted total peak sales of about $1.6 billion.

The recent approval by the US Food and Drug Administration of Celcuity's (CELC) Revtorpyk for breast cancer "validates the multi-node mechanism," Oppenheimer said.

"We believe this validation supports Piktor's probability of success in both breast cancer and endometrial cancer," the note said.

The investment firm added Piktor "could capture meaningful share in community oncology settings with efficacy similar to Revtorpyk."

Oppenheimer started coverage of Faeth Therapeutics with an outperform rating and $60 price target.

Price: $28.44, Change: $-0.80, Percent Change: -2.74%

Related Articles

Wire

AuMEGA Metals Starts Inaugural Diamond Drilling at Canada Targets; Shares Fall 9%

AuMEGA Metals (ASX:AAM) started inaugural diamond drilling at targets at Isle aux Morts Granite and and the adjoining Cape Ray West area along the Cape Ray shear zone in Canada, according to a Tuesday Australian bourse filing.The drilling program is designed to test a series of structural, geochemical, and geophysical targets defined by integrating geological mapping, surface geochemistry, geophysics, and structural interpretation, per the filing.The company's shares fell nearly 9% in recent trading on Tuesday.

ASX:AAM
Wire

Brown & Brown Q2 Adjusted Earnings, Revenue Rise

Brown & Brown (BRO) reported Q2 adjusted earnings late Monday of $1.07 per diluted share, up from $1.03 a year earlier.Analysts polled by FactSet expected $1.08.Revenue in the three months ended June 30 rose to $1.68 billion from $1.29 billion a year earlier.Analysts expected $1.71 billion.The company's shares fell 1.8% in after-hours trading.

$BRO
Wire

Celestica Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Celestica (CLS) reported Q2 adjusted earnings late Monday of $2.54 per diluted share, up from $1.39 a year earlier.Analysts polled by FactSet expected $2.27.Revenue in the three months ended June 30 rose to $4.7 billion from $2.89 billion a year earlier.Analysts expected $4.33 billion.Celestica expects Q3 adjusted EPS of $2.88 to $3.08 on revenue of $5.25 to $5.55 billion.Analysts project EPS of $2.65 on revenue of $4.94 billion.The company boosted full-year guidance to adjusted EPS of $11.30 on revenue of $20.5 billion from the prior forecast of EPS of $10.15 on revenue of $19 billion.Analysts project EPS of $10.13 on revenue of $18.95 billion.Celestica shares rose 9.4% in after-hours trading.

$CLS